Cancer stem cells in prostate adenocarcinoma: A target for new anticancer strategies

Journal of Cellular Physiology

Volumn 216, Issue 3, 2008, Pages 571-575

  Fioriti, D ^a   Mischitelli, M ^a   Di Monaco, F ^a   Di Silverio, F ^a   Petrangeli, E ^a   Russo, G ^b   Giordano, A ^b,c   Pietropaolo, V ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Temple University   (United States)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER STEM CELL; CELL CULTURE; CELL POPULATION; DISEASE COURSE; DISEASE PREDISPOSITION; HUMAN; IN VIVO STUDY; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REVIEW; TARGET CELL;

ADENOCARCINOMA; ANOXIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELLS, CULTURED; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 48749098253     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21493     Document Type: Review

References (64)

1. Antica M, Wu L, Scollay R. 1997. Stem cell antigen 2 expression in adult and developing mice. Immunol Lett 55:47-51.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. 2008. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26:242-245.
3. Bonkhoff H, Remberger K. 1993. Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 422:35-38.
4. Bonkhoff H, Stein U, Remberger K. 1994. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118.
5. Bonkhoff H, Stein U, Aumüller G, Remberger K. 1996. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29:261-267.
6. Brown MD, Gilmore PE, Hart CA, Samuel JD, Ramani VAC, George NJ, Clarke NW. 2007. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate 67:1384-1396.
7. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G. 2005. Isolation of renal progenitor cells from adult human kidney. Am J Pathol 166:545-555.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
9. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339-9344.
10. Classon BJ, Boyd RL. 1998. Thymic-shared antigen-1 (TSA-1). A. lymphostromal cell membrane Ly-6 superfamily molecule with a putative role in cellular adhesion. Dev Immunol 6:149-156.
11. 1 integrin expression. J Cell Sci 114:3865-3872.
12. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951.
13. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. 2000. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275:5512-5520.
14. Drewa T, Styczynski J. 2007. Progenitor cells are responsible for formation primary epithelial cultures in the prostate epithelial model. Int Urol Nephrol 39:851-857.
15. Edwards J, Krishna NS, Grigor KM, Bartlett JM. 2003. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552-556.
16. Fidler IJ, Hart IR. 1982. Biological diversity in metastatic neoplasms: Origins and implications. Science 217:998-1003.
17. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D. 2005. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 319:15-26.
18. Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and Rel proteins: Evolutionary conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
19. Goldie JH, Coldman AJ. 1979. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733.
20. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL, Vervaert CE, Seigler HF. 2006. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142-153.
21. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. 2000. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19:1288-1296.
22. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. 2003. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523.
23. Harris AL. 2002. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
24. Heppner GH. 1984. Tumor heterogeneity. Cancer Res 44:2259-2265.
25. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. 2004. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227.
26. Hudson DL, O'Hare M, Watt FM, Masters JR. 2000. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells. Lab Invest 80:1243-1250.
27. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR. 2001. Epithelial cell differentiation pathways in the human prostate: Identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49:271-278.
28. Isaacs JT, Schulze H, Coffey DS. 1987. Development of androgen resistance in prostatic cancer. Prog Clin Biol Res 243A:21-31.
29. Isaacs JT, Coffey DS. 1989. Etiology and disease process of benign prostatic hyperplasia. Prostate 2:33-50.
30. Kamstrup MR, Gniadecki R, Skovgaard GL. 2007. Putative cancer stem cells in cutaneous malignancies. Exp Dermatol 16:297-301.
31. Kyprianou N, Isaacs JT. 1988. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562.
32. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. 2005. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 11:2591-2596.
33. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. 2002. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161:1467-1474.
34. Liu AY. 2000. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 60:3429-3434.
35. Magi-Galluzzi C, Loda M. 1996. Molecular events in the early phases of prostate carcinogenesis. Eur Urol 30:167-176.
36. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. 2007. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67:3153-3161.
37. Miki J, Rhim JS. 2008. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 11:32-39.
38. O'Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110.
39. Oh WK. 2002. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81-89.
40. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. 2006. Highly purified CD44(+) prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708.
41. Peehl DM. 2004. Are primary cultures realistic models of prostate cancer? J Cell Biochem 91:185-195.
42. Piccirillo SG, Vescovi AL. 2006. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 5:59-81.
43. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. 1998. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95:1735-1740.
44. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
45. Rhim JS. 2000. In vitro human cell culture models for the study of prostate cancer. Prostate Cancer Prostatic Dis 3:229-235.
46. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115.
47. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. 2004. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117:3539-3545.
48. Sandhu C, Peehl DM, Slingerland J. 2000. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Res 60:2616-2622.
49. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. 1996. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58:139-146.
50. Schalken JA, van Leenders G. 2003. Cellular and molecular biology of the prostate: Stem cell biology. Urology 62:11-20.
51. Semenza GL. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor I. Annu Rev Cell Dev Biol 15:551-578.
52. Semenza GL. 2003. Targeting HIF-I for cancer therapy. Nat Rev Cancer 3:721-732.
53. Sherwood ER, Theyer G, Steiner G, Berg LA, Kozlowski JM, Lee C. 1991. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate 18:303-314.
54. Sobel RE, Sadar MD. 2005a. Cell lines used in prostate cancer research: A compendium of old and new lines - Part I. J Urol 173:342-359.
55. Sobel RE, Sadar MD. 2005b. Cell lines used in prostate cancer research: A compendium of old and new lines - Part 2. J Urol 173:360-372.
56. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R, Jeter C. 2007. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol Carcinog 46:1-14.
57. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Cancer, Leukemia Group B Study, 9663. 2003. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678.
58. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. 2000. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97:14720-14725.
59. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. 2000. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 80:1251-1258.
60. Vaupel P, Thews O, Hoeckel M. 2001. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 18:243-259.
61. Vercauteren SM, Sutherland HJ. 2001. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 3:449-459.
62. Weigmann A, Corbeil D, Hellwig A, Huttner WB. 1997. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci 94:12425-12430.
63. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002-5012.
64. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. 2008. Brca 1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10:R10.